Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis.

• Results Overview

  Lebrikizumab, given as an injection every 2 weeks, was significantly more effective than placebo in clearing skin and reducing itch in people with moderate-to-severe eczema over 16 weeks of treatment.

• Study Summary

  Num Participants:

  851

  Study Type:

  Rct

  Control Group:

  Placebo

  Efficacy End Points Treatment:

  {'IGA 0/1': 43.1, 'EASI-75': 58.8}

  Efficacy End Points Control:

  {'IGA 0/1': 12.7, 'EASI-75': 16.2}

  Side Effects Treatment:

  Adverse Event	Severity	Percentage Affected
  Conjunctivitis	Low

  Side Effects Control:

  Adverse Event	Severity	Percentage Affected